[1] Loomba R,Friedman SL,Shulman GI.Mechanisms and disease consequences of nonalcoholic fatty liver disease[J].Cell,2021,184(10):2537-2564.
[2] Huang DQ,El-Serag HB,Loomba R.Global epidemiology of NAFLD-related HCC: Trends,predictions,risk factors and prevention[J].Nat Rev Gastro Hepatol,2020,18(4):223-238.
[3] Zhou J,Zhou F,Wang W,et al.Epidemiological features of NAFLD from 1999 to 2018 in China[J].Hepatology,2020,71(5):1851-1864.
[4] Li YY.Genetic and epigenetic variants influencing the development of nonalcoholic fatty liver disease[J]. World J Gastroenterol,2012(45):6546-6551.
[5] Su Q,Kumar V,Sud N,et al.MicroRNAs in the pathogenesis and treatment of progressive liver injury in NAFLD and liver fibro-sis[J].Adv Drug Deliv Rev,2018,129:54-63.
[6] Chai C,Rivkin M,Berkovits L,et al.Metabolic circuit involving free fatty acids,microRNA 122,and triglyceride synthesis in liver and muscle tissues[J]. Gastroenterology,2017,153(5):1404-1415.
[7] Chai C,Cox B,Yaish D,et al.Agonist of RORA attenuates non-alcoholic fatty liver progression in mice via upregulation of microRNA 122[J].Gastroenterology,2020,159(3):999-1014.
[8] Miyaaki H,Ichikawa T,Kamo Y,et al. Significance of serum and hepatic microRNA-122 levels in patients with non-alcoholic fatty liver disease[J].Liver Int,2014,34(7):e302-e307.
[9] Willeit P,Skroblin P,Kiechl S,et al. Liver microRNAs: Potential mediators and biomarkers for metabolic and cardiovascular disea-se[J].Europ Heart J,2016,37(43):3260-3266.
[10] Estep M,Armistead D,Hossain N,et al.Differential expression of miRNAs in the visceral adipose tissue of patients with non-alcoholic fatty liver disease[J].Aliment Pharmacol Ther,2010,32(3):487-497.
[11] Pirola CJ,Fernández Gianotti T,Castaño GO,et al. Circulating microRNA signature in non-alcoholic fatty liver disease: From serum non-coding RNAs to liver histology and disease pathogene-sis[J]. Gut,2015,64(5):800-812.
[12] Zhang D,Wang Y,Ji Z,et al. Identification and differential expression of microRNAs associated with fat deposition in the liver of Wistar rats with nonalcoholic fatty liver disease[J].Gene,2016,585(1):1-8.
[13] Esau C,Davis S,Murray SF,et al.miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting[J].Cell Metab,2006,3(2):87-98.
[14] Ye D,Zhang T,Lou G,et al. Plasma miR-17,miR-20a,miR-20b and miR-122 as potential biomarkers for diagnosis of NAFLD in type 2 diabetes mellitus patients[J]. Life Sci. 2018,208:201-207.
[15] Ola W,Mehdi M,Stefan E,et al. Molecular interactions between HNF4a,FOXA2 and GABP identified at regulatory DNA elements through ChIP-sequencing[J]. Nucleic Acids Res,2009,37(22):7498-7508.
[16] Hu Y,Du G,Li G,et al. The miR-122 inhibition alleviates lipid accumulation and inflammation in NAFLD cell model[J]. Arch Physiol Biochem,2021,127(5):385-389.
[17] 谢景军,魏从光,张建峰,等. 下调miR-122对非酒精性脂肪性肝炎小鼠的炎症发生及肝细胞凋亡的影响[J].胃肠病学和肝病学杂志,2020,29(8):873-878.
[18] 杨庆宇,郜娜. 白藜芦醇通过miRNA-122调节神经酰胺水平而治疗非酒精性脂肪肝[J]. 中国病理生理杂志,2017,33(8):1506-1513.
[19] Baselga-Escudero L,Blaed C,Ribas-Latre A,et al.Resveratrol and egcg bind directly and distinctively to miR-33a and miR-122 and modulate divergently their levels in hapatic cells[J].Nucleic Acids Res,2014,42(2):882-892.
[20] Rodriguez-Ramiro I,Vauzour D,Minihane AM. Polyphenols and non-alcoholic fatty liver disease: Impact and mechanisms[J]. Proc Nutr Soc,2016,75(1):47-60.
[21] Joven J,Espinel E,Rull A,et al.Plant-derived polyphenols regulate expression of miRNA paralogs miR-103/107 and miR-122 and prevent diet-induced fatty liver disease in hyperlipidemic mice[J].Biochim Biophys Acta,2012,1820(7):894-899.
[22] Zhang Y,Chen SG,Wei CY,et al. Proanthocyanidins from Chinese bayberry (Myrica rubra Sieb. et Zucc.) leaves regulate lipid metabolism and glucose consumption by activating AMPK pathway in HepG2 cells[J]. J Funct Foods,2017,29:217-225.
[23] Su D,Liu H,Qi X,et al.Citrus peel flavonoids improve lipid metabolism by inhibiting miR-33 and miR-122 expression in HepG2 cells[J].Biosci Biotechnol Biochem,2019,83(9):1747-1755.
[24] Ohno M,Shibata C,Kishikawa T,et al.The flavonoid apigenin improves glucose tolerance through inhibition of microma maturation in miRNA103 transgenic mice[J].Sci Rep,2013,3:2553.
[25] Liu M,Yun P,Hu Y,et al.Effects of grape seed proanthocyanidin extract on obesity[J]. Obes Facts,2020,13(2): 279-291.
[26] Del Bas JM,Fernández-Larrea J,Blay M,et al.Grape seed procyanidins improve atherosclerotic risk index and induce liver CYP7A1 and SHP expression in healthy rats[J].FASEB J,2005,19(3):479-481.
[27] Lu RH,Qin CB,Yang F,et al.Grape seed proanthocyanidin extract ameliorates hepatic lipid accumulation and inflammation in grass carp (Ctenopharyngodon idella)[J].Fish Physiol Biochem,2020,46(5):1665-1677.
[28] Su D,Zhang R,Hou F,et al.Lychee pulp phenolics ameliorate hepatic lipid accumulation by reducing miR-33 and miR-122 expression in mice fed a high-fat diet[J]. Food Funct,2017,8(2):808-815.
[29] 邹波. 柿单宁基于AMPK和miRNA调节非酒精性脂肪肝和前脂肪细胞分化的分子机制[D].武汉:华中农业大学,2014.
[30] Boesch-Saadatmandi C,Wagner AE,Wolffram S,et al. Effects of quercetin on inflammatory gene expression in mice liver in vivo-role of redox factor1,miRNA-122 and miRNA-125b[J].Pharmacol Res,2012,65(5):523-530.
[31] Pasdar Y,Oubari F,Zarif MM,et al.Efffects of quercetin supplementation on hematological parameters in non-alcoholic fatty liver disease:a randomized double blind,placebo-controlled pilot study[J].Clin Nutr Res,2020,9(1):11-19.
[32] Zhu X,Bian H,Gao X.The potential mechanisms of berberine in the treatment of nonalcoholic fatty liver disease[J]. Molecules,2016,21(10):1336.
[33] 魏胜男.黄癸固体分散体通过调控肝脏HNF4α/miR122通路纠正糖尿病糖脂代谢紊乱机制研究[D].长春:吉林大学,2016.
[34] Yang L,Liu Q,Zhang H,et al. Silibinin improves nonalcoholic fatty liver by regulating the expression of miR-122: An in vitro and in vivo study[J]. Mol Med Rep, 2021,23(5):335.
[35] 刘丽雅.复方茵陈脂肝颗粒调控miR-122及其下游通路治疗非酒精性脂肪肝病的作用机制研究[D].福州:福建中医药大学,2014.
[36] 张海丛,邵明亮,张巍,等.扶正化瘀片基于miR-122/IL-10因子治疗肝纤维化[J].中医学报,2019,34(6):1317-1321.
[37] Kong Z,Liang N,Yang GL,et al.Xiao Chai Hu Tang,a herbal medicine,for chronic hepatitis B[J].Cochrane Database Syst Rev,2019,2019(11):CD013090.
[38] 赵锦燕.小柴胡汤调控miR-122逆转肝癌多药耐药的作用机制[D].福州:福建中医药大学,2016.
[39] 张广玉,钤培国,孙晓娜,等. 消脂护肝汤对非酒精性脂肪性肝炎患者肝脏的影响[J].中医学报,2019,34(8): 1735-1739.
[40] 陈冉,靳琪鹏,马贵萍,等.冠心康通过miRNA干预HepG2细胞胆固醇代谢的研究[J].上海中医药杂志,2020,54(11):71-77.